SLU-PP-915
updated
SLU-PP-915 is an experimental small molecule, not a peptide, that activates estrogen-related receptors (ERRs), developed as an orally active successor to SLU-PP-332. It is promoted for endurance, fat loss and heart protection. In a 2026 study, mice given it by mouth ran farther and longer on treadmills, but no person has been given it, the heart findings are also from mice, and the fat-loss results often quoted belong to SLU-PP-332. Graded C for preclinical development that includes direct oral mouse results; human benefit and safety are unestablished.
Small-molecule ERR agonist
- Chemically distinct from SLU-PP-332
- Oral activity shown in mice
- Human pharmacokinetics unestablished
What is SLU-PP-915?
SLU-PP-915 is an experimental ERR agonist designed to activate gene programs involved in muscle energy use. It is a small molecule, not a peptide.
It is chemically different from SLU-PP-332. The discovery paper identifies it as compound 10s, a boronic-acid-containing member of a new chemical series.
source: 2023 chemistry · identifying SLU-PP-915, European journal of medicinal chemistry. PMID 37421886.
What does activating ERRs change?
ERRα, ERRβ and ERRγ help regulate mitochondrial and fuel-use genes. SLU-PP-915 activates these receptors in experimental systems.
The 2026 mouse study measured exercise-related gene responses, including Ddit4. A higher gene-expression measurement does not by itself establish better health or stronger muscles in a person.
source: 2023 chemistry · identifying SLU-PP-915
source: 2026 oral study · exercise in mice, The Journal of pharmacology and experimental therapeutics. PMID 41421047.
Did oral SLU-PP-915 improve endurance?
In mice, oral treatment improved treadmill distance and duration in the 2026 study. No human performance trial is cited.
The researchers also measured gene responses during exercise training in mice. They did not test whether the compound can replace training in people.
source: 2026 oral study · exercise in mice
source: ClinicalTrials.gov · no human study listed, PubMed and ClinicalTrials.gov.
Does SLU-PP-915 solve the oral-delivery problem?
It showed oral activity in mice, whereas the same research describes limited oral bioavailability for 332. Human absorption remains unestablished.
| Finding | SLU-PP-332 | SLU-PP-915 |
|---|---|---|
| Exercise effects | Mouse evidence. | Mouse evidence, including oral treatment. |
| Obesity/metabolic-syndrome study | Directly tested in the 2024 study. | Cannot inherit 332’s results. |
| Pressure-overload heart failure | Tested in mice. | Also tested directly in mice. |
| Human benefit or clinical dose | Not established in the cited human evidence. | Not established in the cited human evidence. |
source: 2026 oral study · exercise in mice
source: 2024 metabolic study · obese mice, The Journal of pharmacology and experimental therapeutics. PMID 37739806.
source: 2024 heart study · both compounds in mice, Circulation. PMID 37961903.
What does the 18–28 minute half-life mean?
That is the reported oral half-life in mice in the 2026 study. It is not a measured human half-life.
A separate comparison found similar plasma levels one hour after the first and fourteenth doses. One sampling time cannot exclude accumulation at other times or exposures.
source: 2026 oral study · exercise in mice
Does a short half-life mean short effects?
A drug concentration and a downstream gene response can follow different timelines. The study does not provide a human duration of benefit or a dosing interval.
What about heart protection and fat loss?
The direct heart-failure findings come from mice. The older obesity and fat-accumulation results commonly discussed with this family belong to SLU-PP-332.
The heart study tested both compounds and reported improvements in function, fibrosis, and survival in a mouse pressure-overload model. It did not study weight loss or heart-failure treatment in patients.
Has anyone been given it in a clinical study?
The cited records contain no human administration study. Human liver preparations have been used to study its metabolism outside the body.
Incubating a compound with microsomes or liver S9 fractions can identify metabolites. It cannot establish how a whole person handles the drug, which interactions matter clinically, or how long it is detectable after use.
source: 2026 metabolism study · liver preparations, Rapid communications in mass spectrometry : RCM. PMID 41588687.
What adverse effects are known?
The cited records contain no human adverse-event study establishing common side effects or a tolerated exposure range.
Mouse oral bioavailability is a delivery finding, not a safety result. Available studies leave long-term organ effects, reproductive safety and drug interactions unresolved.
Is there a validated way to dose or combine it?
The cited records contain no human dose, cycle, combination, or stopping plan. Copying mouse schedules does not establish one.
Available human evidence does not show that adding SLU-PP-915 to SLU-PP-332, a GLP-1 medicine or a stimulant improves benefit or limits harm. The published comparison of 332 and 915 is not a trial of taking both together.
Studies and sources
2024 metabolic study · obese mice
Animal experiments
The Journal of pharmacology and experimental therapeutics. PMID 37739806.
In diet-induced obese and genetically obese mice, SLU-PP-332 increased energy expenditure and fatty-acid oxidation, reduced fat accumulation and improved insulin sensitivity.
These results belong to SLU-PP-332. They are not clinical outcomes and cannot automatically be assigned to SLU-PP-915.
Read the original source2023 chemistry · identifying SLU-PP-915
Medicinal chemistry and preclinical experiments
European journal of medicinal chemistry. PMID 37421886.
Researchers developed a chemically distinct series of ERR agonists. SLU-PP-915, compound 10s, contains a boronic-acid group and showed improved metabolic stability in microsomal assays, with ERR target-gene effects in cells and animals.
Stability in an enzyme preparation does not establish a human half-life.
Read the original source2026 oral study · exercise in mice
Animal experiments
The Journal of pharmacology and experimental therapeutics. PMID 41421047.
Oral SLU-PP-915 improved mouse treadmill distance and duration. Exercise-related gene responses were also measured, including with training. The paper identifies poor oral bioavailability as a limitation of SLU-PP-332.
- The publisher text reports oral mouse half-lives of 18–28 minutes.
- A repeated-dosing comparison sampled plasma one hour after the first and fourteenth doses; similar levels at that time do not exclude accumulation at every other time point.
Mouse oral activity is not evidence that a retail product is effective or safe in humans.
Read the original source2024 heart study · both compounds in mice
Animal and mechanistic experiments
Circulation. PMID 37961903.
SLU-PP-332 and SLU-PP-915 improved several outcomes in mouse pressure-overload heart failure, including contractile function, fibrosis and survival. The study also investigated ERR-dependent metabolic mechanisms.
Neither compound has a demonstrated heart-failure treatment effect in patients from this study.
Read the original source2026 metabolism study · liver preparations
In vitro metabolism study
Rapid communications in mass spectrometry : RCM. PMID 41588687.
Human liver S9 fractions and microsomes generated identifiable metabolites of both compounds. This was laboratory metabolism and analytical-method work.
No human participant received either drug. This does not establish clinical clearance, interactions or a detection window.
Read the original sourceClinicalTrials.gov · no human study listed
Registry and literature record
PubMed and ClinicalTrials.gov.
The cited records contain no human administration, pharmacokinetic, safety, or efficacy study for SLU-PP-915.
Read the original sourceWhy is SLU-PP-915 in C tier?
C reflects preclinical development, including direct oral mouse findings. It is not a rating of proven human performance benefit or safety.
how tiers are graded: methodology · every cited source · about reptides.
Research reference, not medical advice. Entries distinguish product labels, study doses and reported protocols. Check the linked source for the product, route and population.